GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Accounts Receivable

PARNF (Parnell Pharmaceuticals Holdings) Accounts Receivable : $1.20 Mil (As of Dec. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Parnell Pharmaceuticals Holdings's accounts receivables for the quarter that ended in Dec. 2018 was $1.20 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Parnell Pharmaceuticals Holdings's Days Sales Outstanding for the quarter that ended in Dec. 2018 was 11.54.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Parnell Pharmaceuticals Holdings's Net-Net Working Capital per share for the quarter that ended in Dec. 2018 was $-1.78.


Parnell Pharmaceuticals Holdings Accounts Receivable Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Accounts Receivable Chart

Parnell Pharmaceuticals Holdings Annual Data
Trend Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Accounts Receivable
Get a 7-Day Free Trial 2.30 2.48 1.20 0.73 1.20

Parnell Pharmaceuticals Holdings Semi-Annual Data
Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Accounts Receivable Get a 7-Day Free Trial 2.30 2.48 1.20 0.73 1.20

Parnell Pharmaceuticals Holdings Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Parnell Pharmaceuticals Holdings Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Parnell Pharmaceuticals Holdings's Days Sales Outstanding for the quarter that ended in Dec. 2018 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=1.203/19.031*91
=11.54

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Parnell Pharmaceuticals Holdings's accounts receivable are only considered to be worth 75% of book value:

Parnell Pharmaceuticals Holdings's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2018 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(3.155+0.75 * 1.203+0.5 * 2.29-37.285
-0-0)/18.0238
=-1.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Parnell Pharmaceuticals Holdings Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Parnell Pharmaceuticals Holdings Business Description

Traded in Other Exchanges
N/A
Address
476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015
Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.